Telix Advances First Radiopharmaceutical Phase 3 Trial for Recurrent Glioblastoma

Event summary

  • Telix dosed the first patient in its Phase 3 IPAX-BrIGHT trial for TLX101-Tx in recurrent glioblastoma on April 15, 2026.
  • The trial is the first radiopharmaceutical therapy Phase 3 study for glioblastoma, targeting the L-type amino acid transporter 1 (LAT1).
  • IPAX-BrIGHT is a global, multicenter, open-label study comparing TLX101-Tx with chemotherapy (lomustine) against chemotherapy alone.
  • TLX101-Tx has shown promising median overall survival data in earlier trials, including 13 months from treatment initiation in IPAX-1.
  • The trial has received regulatory approval in Australia, Austria, Belgium, and the Netherlands, with additional jurisdictions pending.

The big picture

Telix's Phase 3 trial for TLX101-Tx marks a significant step in addressing the critical unmet need in treating recurrent glioblastoma, an area with limited innovation for over two decades. The trial's success could validate radiopharmaceutical therapies as a new standard in neuro-oncology, potentially disrupting the current treatment landscape dominated by surgical resection, radiotherapy, and chemotherapy. The strategic focus on targeting LAT1 to cross the blood-brain barrier highlights Telix's innovative approach to delivering therapy directly to tumors.

What we're watching

Clinical Efficacy
Whether TLX101-Tx can demonstrate superior efficacy over existing chemotherapy options in the Phase 3 trial.
Regulatory Pathway
The pace at which Telix secures additional regulatory approvals for the IPAX-BrIGHT trial beyond the current jurisdictions.
Commercialization Potential
How the success of TLX101-Tx could position Telix as a leader in radiopharmaceutical therapies for glioblastoma.

Related topics

Oncology